MRGCX | VITSX | MRGCX / VITSX | |
Total Expense Ratio | 1.64 | 0.03 | 5,467% |
Annual Report Gross Expense Ratio | 1.65 | 0.03 | 5,500% |
Fund Existence | 29 years | 28 years | - |
Gain YTD | 9.109 | 12.267 | 74% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 1000 | 5000000 | 0% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 6.66B | 1.95T | 0% |
Annual Yield % from dividends | 0.00 | 1.17 | - |
Returns for 1 year | 2.00 | 14.92 | 13% |
Returns for 3 years | 44.25 | 79.19 | 56% |
Returns for 5 years | 44.20 | 95.37 | 46% |
Returns for 10 years | 93.76 | 248.55 | 38% |
1 Day | |||
---|---|---|---|
STOCK / NAME | Price $ | Chg $ | Chg % |
FULC | 8.84 | 0.34 | +4.00% |
Fulcrum Therapeutics | |||
PAC | 248.56 | 1.05 | +0.42% |
Grupo Aeroportuario del Pacifico SAB de CV Amer Dep Shares (each rep 10 Ser B shares) | |||
ETNB | 14.70 | N/A | N/A |
89bio | |||
KAVL | 0.46 | -0.01 | -2.61% |
Kaival Brands Innovations Group | |||
CNTB | 1.58 | -0.11 | -6.51% |
Connect Biopharma Holdings Limited |